Annotation Detail

Information
Associated Genes
CD274
Associated Variants
CD274 EXPRESSION
CD274 EXPRESSION
Associated Disease
Merkel cell carcinoma
Source Database
CIViC Evidence
Description
Patients with Merkel Cell Carcinoma (n=26) were enrolled to receive pembrolizumab. Of these patients, 25 were evaluated for response rate to pembrolizumab and PD-L1 (CD274) expression. The response rate to pembrolizumab was 56% (95%CI: 35-76%), however, there was no correlation between PD-L1 expression (cutoff >1%) on tumor cells or on infiltrating immune cells and clinical response to pembrolizumab (P=0.61).
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1578
Gene URL
https://civic.genome.wustl.edu/links/genes/11335
Variant URL
https://civic.genome.wustl.edu/links/variants/276
Rating
2
Evidence Type
Predictive
Disease
Merkel Cell Carcinoma
Evidence Direction
Does Not Support
Drug
Pembrolizumab
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
27093365
Drugs
Drug NameSensitivitySupported
PembrolizumabSensitivityfalse